Featured Story | By Annalee Armstrong After a summer of deals, Ipsen is closing out the year with one last hurrah. The rare-disease-focused biopharma will partner with Genfit on a liver disease drug in a tie-up potentially worth a half-billion dollars over time. read more |
| |
|---|
|
Top Stories By Kyle LaHucik Just like its approval request for a phase 2 ALS drug, Amylyx Pharmaceuticals is once again skirting convention and going forward with an initial public offering when the biotech market appears to be dipping. read more By Kyle LaHucik With 150 biotechs to its name, Omega Funds closed its seventh and largest fund with $650 million to incubate drug developers, lead early financing rounds and back older startups on the brink of "cracking the problem." read more Sponsored by: Precision for Medicine As technologies and methodologies advance, so do the potential applications for biospecimens. In this article, we explore seven uses of FFPE, ranging from the common to the cutting-edge. read more By Kyle LaHucik Pfizer and Novartis' venture arms have joined investment firms in backing a $119 million series B for Anaveon. The Swiss biotech will deploy the proceeds on a phase 1/2 study in solid tumors. read more By Annalee Armstrong Roche’s Spark Therapeutics unit is pitching $575 million into a new gene therapy manufacturing facility at Drexel University’s Philadelphia campus that will work towards the next generation of genetic medicines. read more By Kevin Dunleavy What do you get when you add the omicron variant to reduced effectiveness for Regeneron and Eli Lilly antibodies and a less-than-stellar report on Merck's ballyhooed antiviral? Mammoth sales for Pfizer's COVID-19 franchise, analysts say. Think $50 billion to $60 billion at peak—and a whopping $25 billion for the vaccine alone in 2027. read more By Angus Liu Borrowing a concept from computation, scientists at ETH Zurich created genetic “logic gates” that can differentiate between tumor and nontumor cells based on their molecular profiles. A gene therapy using the system significantly reduced tumor burden in mice with liver cancer while sparing healthy cells. read more By Andrea Park The deal folds Soliton’s flagship Resonic tattoo- and cellulite-removal device into the portfolio of AbbVie's medical aesthetics subsidiary. read more By Angus Liu Biogen knew what was coming: After a drug review committee's negative “trend vote,” a rejection of Aduhelm from EU authorities seemed inevitable. So when the rebuff did come, the biotech pounced. read more By Heather Landi Oracle is in talks to buy healthcare IT giant Cerner, according to people familiar with the matter, a deal that could be worth around $30 billion, the Wall Street Journal reported. read more By Angus Liu Merck and Eisai's Lenvima failed a Keytruda combo trial in newly diagnosed lung cancer. Johnson & Johnson and Legend Biotech's CAR-T posted a long tail to disease progression. AstraZeneca and Samsung Biologics included AZ's COVID antibody in their contract manufacturing deal. And more. read more By Kyle LaHucik Abbott CEO and President Robert Ford becomes chair of the board as two-decade leader Miles White retires. Gritstone's chief medical officer leaves to helm the same post at Neogene Therapeutics. Former Iterum Therapeutics vice president returns as chief medical officer after brief stint away. read more Resources Sponsored by: BBK Worldwide New survey results and insights help clinical trial sponsors improve diversity and inclusion, enroll faster, and keep participants engaged longer. Sponsored by: WIRB - Copernicus Group Sites receiving augmentation support enroll more than 30,000 patients in just over three months. See how additional site resources can make a difference. Sponsored by: GLG A major Korean biopharmaceutical company wanted to gather unbiased opinions on a new cancer treatment product. Fill out our form to learn more. Sponsored by: GLG Download now to learn how GLG helped a biotech company plan for the demand of a new drug/device combination by commissioning a forecasting study. Sponsored by: Thermo Fisher Scientific A variety of genetic analysis methods are valuable in ensuring that ex vivo human cells to be used for cell-based therapies are correctly identified, have the correct characteristics, and are free of contaminants. Sponsored by: Thermo Fisher Scientific Learn how a CDMO partnered with Thermo Fisher Scientific to manage high-volume process liquid and buffer preparation scale-up. Download the free case study from Thermo Fisher Scientific Sponsored by: Clario This whitepaper addresses where AI can make the biggest impact in clinical trials. The stakes are too high for patients to leave decision-making to machines, but AI can lend administrative support that empowers staff and medical experts alike to carry out their jobs more effectively. Sponsored by: Medable, Inc. Find out how to improve clinical protocol adherence, and thus patient outcomes, by 15%+ with Medable’s latest White Paper. Sponsored by: IQVIA Learn how to elevate your omnichannel marketing strategy with Next Best - a combination of data and analytics, deployed to facilitate decision making. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Informa Pharma Intelligence and Oracle Health Sciences New market research provides valuable insight into the impact of adaptations made in clinical trials during the pandemic. Sponsored by: Thermo Fisher Scientific Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your biologics workflow. Download the free whitepaper from Thermo Fisher Scientific Sponsored by: Box Read Get to Know Cloud Content Management for Life Sciences and learn how to eliminate silos across all workflows, from R&D to commercialization. | 
.jpg/shutterstock_289976045%281%29.jpg/71a2bfbc2c5a7e87ec637aac11fa59e9)
